All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Influenza is a significant local and global public health problem that causes substantial year-round morbidity and mortality \[[@pone.0154970.ref001]\]. Several surveillance systems monitor influenza disease activity with the aim of better understanding its epidemiology and the impact of control measures \[[@pone.0154970.ref002]--[@pone.0154970.ref007]\]. However, current surveillance systems suffer from several limitations, including non-systematic sampling, incomplete case ascertainment, lack of adjustment for confounders, scarcity of information on the impact of different influenza viruses, sparse numbers, lack of consensus about case definition and risk factors, and a lack of comparison groups \[[@pone.0154970.ref008]--[@pone.0154970.ref010]\]. Also, the value of the resulting analyses is often limited by a lack of adjustment for confounders and relatively small sample sizes. These limitations are especially notable for the hospital setting, even though severe influenza is one of the most influential health economic parameters in cost-effectiveness calculations \[[@pone.0154970.ref009],[@pone.0154970.ref011],[@pone.0154970.ref012]\].

Identifying risk factors for severe outcomes and complications is important for reducing influenza-related morbidity and mortality and for guiding control measures against influenza. To assess the impact of the different influenza viruses on clinically meaningful outcomes in at-risk populations, extensive data are needed from geographically diverse settings over several influenza seasons and collected using a common core protocol.

The Global Influenza Hospital Surveillance Network (GIHSN) was established in 2012 as a public-private partnership to obtain valid epidemiologic data on influenza admissions, with the objective of informing influenza prevention and control policies. The GIHSN, which included hospitals in Russia, China, Turkey, and Spain during the 2013/2014 influenza season \[[@pone.0154970.ref006]\], uses a common core protocol to promote consistent eligibility criteria, case definition, and systematic swabbing. Consistency of the information collected is further facilitated by using reverse transcription-polymerase chain reaction (RT-PCR) to confirm influenza infection, by following standard operating procedures, and by using a shared core questionnaire to collect patient information \[[@pone.0154970.ref006],[@pone.0154970.ref013]\].

Here, we describe the epidemiology of hospital admissions with influenza during the 2013/2014 influenza season in the GIHSN Northern hemisphere participating sites. We also determine the impact of underlying patient characteristics on the risk of hospital admission and complications due to influenza overall and due to influenza A(H1N1)pdm09, A(H3N2), and B/Yamagata lineage.

Methods {#sec006}
=======

Study design and participants {#sec007}
-----------------------------

This study employed a prospective active surveillance approach to collect epidemiological and virological data for the 2013/2014 Northern hemisphere influenza season. The participating sites included four hospitals in the Russian Federation, seven in Turkey, two in China, and six in Spain ([S1 Table](#pone.0154970.s003){ref-type="supplementary-material"}).

The methods used in this study were described previously \[[@pone.0154970.ref006],[@pone.0154970.ref013],[@pone.0154970.ref014]\]. Briefly, eligible admissions included non-institutionalized residents in the predefined catchment areas of the participating hospitals, hospitalized in the last 48 h, and with presenting complaints potentially associated with influenza ([S2](#pone.0154970.s004){ref-type="supplementary-material"} and [S3](#pone.0154970.s005){ref-type="supplementary-material"} Tables). The study activities were performed over influenza circulation periods defined using pre-specified criteria ([S3 Table](#pone.0154970.s005){ref-type="supplementary-material"}). The study protocol was approved by the institutional review board of each participating site, Comité Ético de la Dirección General de Salud Pública y Centro Superior de Investigación en Salud Pública (CEIC-DGSP-CSISP); Ethical Committee of Hospital \#1 for Infectious Diseases of Moscow Health Department; Ethics Committee of the Research Institute of Influenza, St. Petersburg; Istanbul University, Istanbul Faculty of Medicine, Ethical Committee for Clinical Research. The study was carried in China by the Chinese Center for Disease Control and Prevention, Beijing, China as part of the implementation of the national Severe Acute Respiratory Infections (SARI) surveillance program in China for purposes of communicable disease control. Ethical approval was not required but informed oral consent was sought before inclusion. All subjects or legal representatives provided written or oral informed consent.

Inclusion criteria {#sec008}
------------------

Eligible admissions were approached by healthcare professionals trained to follow the GIHSN generic study protocol ([S2](#pone.0154970.s004){ref-type="supplementary-material"} and [S3](#pone.0154970.s005){ref-type="supplementary-material"} Tables). All sites applied the same selection criteria to eligible admissions. Patients ≥5 years of age had to have influenza like illness (ILI) symptoms \[[@pone.0154970.ref015]\], defined as at least one systemic symptom (fever or feverishness, malaise, headache, or myalgia) and at least one respiratory symptom (cough, sore throat, or shortness of breath), and hospitalization within 7 days of the onset of ILI. Patients \<5 years of age had to be admitted to hospital within 7 days of the appearance of symptoms potentially associated with influenza. Patients who had been discharged from a hospital within 30 days of the current episode were excluded.

Sampling {#sec009}
--------

After patients or legal representatives provided signed, informed consent, a combined nasopharyngeal and pharyngeal swab (patients ≥14 years of age) or both nasopharyngeal and nasal swabs (patients \<14 years old) were obtained from included subjects in the Russian Federation, Turkey, and Spain. In China, two combined pharyngeal swabs were obtained from all patients regardless of age. Both swabs were collected in the same test tube and sent to the site's laboratory for testing ([S1 Text](#pone.0154970.s007){ref-type="supplementary-material"}).

Covariates {#sec010}
----------

Demographic, clinical, and epidemiological information was collected from all enrolled patients as previously described \[[@pone.0154970.ref006],[@pone.0154970.ref013]\]. Baseline data collected included date of symptom onset, date of admission, sex, age, presence of chronic conditions, pregnancy status, obesity, smoking habits, hospital admissions in the past 12 months, outpatient consultations in the previous 3 months, socioeconomic status based on occupation \[[@pone.0154970.ref016]\], functional status in patients ≥65 years of age (Barthel index) \[[@pone.0154970.ref017]\], and time elapsed between illness onset and swabbing. Vaccination in the previous and current season was ascertained by recall, clinical records, or vaccination registries. Date of discharge or death while hospitalized, intensive care unit (ICU) admission, and main diagnoses at discharge or at time of death were also recorded.

Obesity was defined as a body mass index ≥30 kg/m^2^ for subjects ≥18 years of age. For subjects \<18 years of age, obesity criteria were applied following World Health Organization guidelines \[[@pone.0154970.ref018],[@pone.0154970.ref019]\].

Laboratory methods {#sec011}
------------------

Influenza infection was confirmed by RT-PCR for influenza A (subtypes H3 and H1pdm09) and B (Yamagata and Victoria lineages) ([S1 Text](#pone.0154970.s007){ref-type="supplementary-material"}).

Outcomes {#sec012}
--------

Admissions with a positive RT-PCR result were considered influenza-related admissions. The distribution of hospital admission according to RT-PCR result was described by site and risk group. Secondary outcomes included hospital admissions by subtype for influenza A(H1N1)pdm09, A(H3N2), and B/Yamagata lineage, by site and risk group.

Data analysis {#sec013}
-------------

Statistical analyses were performed using Stata version 14.0 (College Station, TX). All analyses were restricted to periods with influenza admissions. Records with missing laboratory results or date of illness onset were excluded. Only admissions swabbed within 7 days after symptom onset were included in the analysis. The significance of differences among groups or categories was estimated by the likelihood ratio test, t-test, or nonparametric tests as required. Additional analyses included the number and temporal sequence of admissions and the distribution of type subtypes of viruses, sociodemographic characteristics, underlying conditions and exposures, ICU admission, length of stay, in-hospital death, major complications, and main diagnoses at discharge \[[@pone.0154970.ref020]\].

Risk for influenza related admission {#sec014}
------------------------------------

To describe the major determinants for admission with influenza (vs. influenza-negative admission), a stepwise logistic regression model was fitted by including all risk factors at P\<0.2.

Confounding and adjusted estimates {#sec015}
----------------------------------

Adjusted odds ratios (aORs) for RT-PCR-positive vs. RT-PCR-negative admissions in the presence of major risk factors of interest were estimated by multivariate logistic regression using minimal sufficient adjustment sets of covariates identified as confounders by causal diagrams \[[@pone.0154970.ref021],[@pone.0154970.ref022]\]. When more than one alternative for modeling was possible, we used the most explanative and parsimonious model according to Akaike's information criterion \[[@pone.0154970.ref023]\]. To estimate risk factors for specific strains, admissions positive for other influenza strains were excluded. When comparing the effects of comorbidities, the comparison group was individuals without underlying conditions. For pregnant women, the comparison group was women 15 to 45 years of age. For variables with more than one category, the lowest was used as a baseline for comparison. Restricted cubic spline functions were used to model the effect of age and calendar on influenza-associated events, with the best modeling (number of knots) option decided using Akaike's information criterion \[[@pone.0154970.ref023]\]. The likelihood ratio test was used to estimate significance and to explore linearity and effect modification.

Clustering {#sec016}
----------

To account for the possible effect of study site, data were fitted to a random effects logistic regression model including site as a cluster variable. Likelihood ratio tests were used to check for the potential effect of clustering by site \[[@pone.0154970.ref024]\]. The adjusted effect of site in the probability of influenza with admission was estimated.

Heterogeneity {#sec017}
-------------

Heterogeneity in the effects of risk factors by influenza strain and site were quantified using the I^2^ test. Heterogeneity was defined as an I^2^\>50% \[[@pone.0154970.ref025],[@pone.0154970.ref026]\]. Forest plots were used to present the effect size of each risk factor by strain.

Sample size {#sec018}
-----------

Assuming that 20% of admissions in the control group are due to influenza and with a type II error \<20% and a type I error ≤5% \[[@pone.0154970.ref027]\], 1825 patients are needed to detect a significant impact of a comorbid condition at an odds ratio of 1.25, 525 at an odds ratio of 1.50, and 175 at an odds ratio of 2.0.

Results {#sec019}
=======

Included patients {#sec020}
-----------------

Between December 2013 and June 2014, 9507 eligible admissions were identified by the 19 participating hospitals. Of these, 5303 (56%) were included and swabbed ([Table 1](#pone.0154970.t001){ref-type="table"}). Major reasons for exclusion were the absence of ILI symptoms within 7 days of admission (n = 1781 \[19%\]), swabbing more than 7 days after symptoms onset (n = 1006 \[11%\]), not obtaining informed consent (n = 591 \[6%\]), and recruitment during periods without influenza admissions (n = 279 \[3%\]) ([Table 1](#pone.0154970.t001){ref-type="table"}).

10.1371/journal.pone.0154970.t001

###### Flow of study patients and RT-PCR results.

![](pone.0154970.t001){#pone.0154970.t001g}

                                                                        St. Petersburg                              Moscow   Turkey   Beijing   Valencia   Total                                     
  --------------------------------------------------------------------- ------------------------------------------- -------- -------- --------- ---------- ------- ----- ------ ------ ------ ------ ------
  Excluded from the analysis                                                                                                                                                                         
      Nonresident                                                       11                                          0.6      63       3.61      127        8.4     1     0.2    49     1.3    251    2.6
      Institutionalized                                                 5                                           0.3      11       0.63      1          0.1     5     0.8    11     0.3    33     0.3
      Unable to communicate                                             28                                          1.6      47       2.70      21         1.4     8     1.2    175    4.5    279    2.9
      Did note provide consent                                          74                                          4.3      59       3.38      39         2.6     69    10.5   71     1.8    312    3.3
      Previous discharge from hospital \<30 days                        13                                          0.8      44       2.52      152        10.1    8     1.2    27     0.7    244    2.6
      No ILI symptoms, ≥5 years of age                                  4                                           0.2      39       2.24      558        37.0    40    6.1    1140   29.3   1781   18.7
      Swabbed \>7 days after onset of symptoms (all ages)               286                                         16.7     149      8.55      103        6.8     61    9.3    407    10.5   1006   10.6
      Sample inadequate                                                 0                                           0.0      0        0.00      0          0.0     0     0.0    5      0.1    5      0.1
      Previous influenza infection                                      1                                           0.1      1        0.06      9          0.6     0     0.0    3      0.1    14     0.1
      Recruited in weeks without laboratory-confirmed Influenza cases   35                                          2.0      70       4.02      13         0.9     42    6.4    119    3.1    279    2.9
  Included in the analysis                                              1256                                        73.3     1260     72.29     486        32.2    421   64.3   1880   48.4   5303   55.8
  RT-PCR result                                                                                                                                                                                      
      Negative                                                          1026                                        81.7     979      77.7      372        76.5    331   78.6   1509   80.3   4217   79.5
      Influenza positive                                                230[^a^](#t001fn001){ref-type="table-fn"}   18.3     281      22.3      114        23.5    90    21.4   371    19.7   1086   20.5
      Influenza A(H1N1)                                                 25                                          2.0      27       2.1       0          0.0     15    3.6    295    15.7   362    6.8
      Influenza A(H3N2)                                                 156                                         12.4     186      14.8      90         18.5    35    8.3    67     3.6    534    10.1
      Influenza A/not typed                                             23                                          1.8      7        0.6       0          0.0     1     0.2    9      0.5    40     0.8
      Influenza B/Yamagata                                              15                                          1.2      52       4.1       24         4.9     39    9.3    0      0.0    130    2.5
      Influenza B/Victoria                                              0                                           0.0      3        0.2       0          0.0     0     0.0    0      0.0    3      0.1
      Influenza B/not typed                                             12                                          1.0      6        0.5       0          0.0     0     0.0    0      0.0    18     0.3

^a^ The number of influenza-positive subjects does not match the sum of the individual strains because one subject was infected with both A(H1N1) and A(H3N2) influenza.

Of the 5303 admissions, 1086 (21%) had laboratory-confirmed influenza ([Table 1](#pone.0154970.t001){ref-type="table"}, [Fig 1](#pone.0154970.g001){ref-type="fig"}). The lowest percentage of influenza positivity was in St. Petersburg (18%) and the highest was in Turkey (24%). Ascertainment of positive admission was earlier in Turkey (week 49/2013) and Valencia (week 51/2013) than in Moscow (week 2/2014), Beijing (week 2/2014), or St. Petersburg (4/2014). The number of consecutive weeks with influenza-positive admissions ranged from 13 to 21 (13 in Valencia, 14 in Beijing, 17 in St. Petersburg and Turkey, and 21 in Moscow).

![Admissions with influenza by site, by epidemiological week, and by influenza virus type, subtype, or lineage.](pone.0154970.g001){#pone.0154970.g001}

Circulating influenza strains {#sec021}
-----------------------------

Overall, influenza A(H3N2) was the predominant circulating strain (n = 543, 50%), followed by A(H1N1)pdm09 (n = 362; 34%) and B/Yamagata lineage (n = 130; 12%) ([Table 1](#pone.0154970.t001){ref-type="table"}, [Table 2](#pone.0154970.t002){ref-type="table"} and [Fig 1](#pone.0154970.g001){ref-type="fig"}). Only three admissions had B/Victoria lineage in Moscow. At each site, the influenza viruses detected varied during the season.

10.1371/journal.pone.0154970.t002

###### Characteristics of included patients according to RT-PCR result.

![](pone.0154970.t002){#pone.0154970.t002g}

                                                                                 Influenza negative   Influenza positive   A(H3N2)[^a^](#t002fn001){ref-type="table-fn"}   A(H1N1)p[^a^](#t002fn001){ref-type="table-fn"}     B/Yamagata[^a^](#t002fn001){ref-type="table-fn"}                                                                                                      
  ------------------------------------------------------------------------------ -------------------- -------------------- ----------------------------------------------- -------------------------------------------------- -------------------------------------------------- ------------------------------------------- ----- ------------------------------------------- ---- -------------------------------------------
  Age in years, mean (standard deviation)                                        30.9 (31.7)          34.9 (28.6)          30 (27.0)                                       45.8[\*](#t002fn006){ref-type="table-fn"} (29.3)   30.6 (25.6)                                                                                                                                           
  Age group                                                                                                                                                                                                                                                                                                                                                                         
      0--5 months                                                                503                  11.9                 54                                              5                                                  22                                                 4.1                                         21    5.8                                         3    2.3
      6--11 months                                                               279                  6.6                  36                                              3.3                                                20                                                 3.7                                         11    3                                           1    0.8
      1--4 years                                                                 905                  21.5                 181                                             16.7                                               100                                                18.7                                        44    12.2                                        23   17.7
      5--17 years                                                                291                  6.9                  102                                             9.4                                                57                                                 10.7                                        14    3.9                                         24   18.5
      18--49 years                                                               929                  22.0                 349                                             32.1                                               214                                                40.1                                        70    19.4                                        49   37.7
      50--64 years                                                               337                  8.0                  132                                             12.2                                               29                                                 5.4                                         87    24.1                                        11   8.5
      65--74 years                                                               304                  7.2                  94                                              8.7                                                32                                                 6.0                                         51    14.1                                        8    6.2
      75--84 years                                                               426                  10.1                 106                                             9.8                                                47                                                 8.8                                         47    13                                          9    6.9
      ≥85 y                                                                      243                  5.8                  32                                              2.9                                                13                                                 2.4                                         16    4.4                                         2    1.5
  Female                                                                         1829                 43.4                 547                                             50.4[\*](#t002fn006){ref-type="table-fn"}          284                                                53.2[\*](#t002fn006){ref-type="table-fn"}   165   45.7                                        72   55.4[\*](#t002fn006){ref-type="table-fn"}
  Number of underlying comorbidities                                                                                                                                                                                                                                                                                                                                                
      0                                                                          2789                 66.1                 656                                             60.4                                               345                                                64.6                                        165   45.7                                        94   72.3
      1                                                                          732                  17.4                 260                                             23.9[\*](#t002fn006){ref-type="table-fn"}          122                                                22.8[\*](#t002fn006){ref-type="table-fn"}   109   30.2[\*](#t002fn006){ref-type="table-fn"}   24   18.5
      ≥2                                                                         696                  16.5                 170                                             15.7                                               67                                                 12.5                                        87    24.1[\*](#t002fn006){ref-type="table-fn"}   12   9.2
  Underlying chronic diseases                                                                                                                                                                                                                                                                                                                                                       
      Cardiovascular disease                                                     685                  17.1                 189                                             18.4                                               91                                                 17.9                                        80    22.8[\*](#t002fn006){ref-type="table-fn"}   13   12.3
      COPD                                                                       607                  15.2                 139                                             13.6                                               44                                                 8.7[\*](#t002fn006){ref-type="table-fn"}    79    22.5[\*](#t002fn006){ref-type="table-fn"}   13   12.3
      Asthma                                                                     194                  4.8                  76                                              7.4[\*](#t002fn006){ref-type="table-fn"}           35                                                 6.9                                         31    8.8[\*](#t002fn006){ref-type="table-fn"}    10   9.4
      Immunodeficiency/organ transplant                                          38                   0.9                  16                                              1.6                                                13                                                 2.6[\*](#t002fn006){ref-type="table-fn"}    3     0.9                                         0    0
      Diabetes                                                                   390                  9.7                  105                                             10.2                                               30                                                 5.9[\*](#t002fn006){ref-type="table-fn"}    67    19.1[\*](#t002fn006){ref-type="table-fn"}   5    4.7
      Chronic renal impairment                                                   167                  4.2                  57                                              5.6                                                24                                                 4.7                                         28    8[\*](#t002fn006){ref-type="table-fn"}      4    3.8
      Chronic rheumatologic disease                                              12                   0.5                  11                                              1.7[\*](#t002fn006){ref-type="table-fn"}           6                                                  1.4                                         1     1.8                                         4    3.8[\*](#t002fn006){ref-type="table-fn"}
      Chronic neuromuscular disease                                              94                   2.3                  19                                              1.9                                                14                                                 2.8                                         3     0.9[\*](#t002fn006){ref-type="table-fn"}    2    1.9
      Active neoplasm                                                            130                  3.2                  29                                              2.8                                                13                                                 2.6                                         15    4.3                                         0    0
      Chronic liver disease                                                      65                   1.6                  23                                              2.2                                                10                                                 2.0                                         11    3.1                                         1    0.9
      Autoimmune disease                                                         32                   0.8                  16                                              1.6[\*](#t002fn006){ref-type="table-fn"}           8                                                  1.6                                         6     1.7                                         2    1.9
  Pregnant status (women 15--45 years)                                           181                  44.7                 156                                             70.3[\*](#t002fn006){ref-type="table-fn"}          100                                                71.9[\*](#t002fn006){ref-type="table-fn"}   18    51.4.                                       33   86.8[\*](#t002fn006){ref-type="table-fn"}
  Obese[^b^](#t002fn002){ref-type="table-fn"}                                    701                  16.9                 194                                             18.1                                               77                                                 14.6                                        95    26.5[\*](#t002fn006){ref-type="table-fn"}   14   10.9
  Outpatient visits in the last 3 months[^c^](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                      
      0                                                                          1283                 30.5                 306                                             28.2                                               172                                                32.2                                        85    23.6                                        30   23.1
      1                                                                          919                  21.8                 241                                             22.2                                               93                                                 17.4                                        112   31.1                                        19   14.6
      ≥2                                                                         2011                 47.7                 538                                             49.6                                               269                                                50.4                                        163   45.3                                        81   62.3[\*](#t002fn006){ref-type="table-fn"}
  Smoking habits[^d^](#t002fn004){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                              
      Current smoker                                                             1009                 23.9                 274                                             25.3                                               124                                                23.2                                        100   27.7                                        31   24
      Past smoker                                                                813                  19.3                 200                                             18.4                                               96                                                 18.0                                        75    20.8                                        24   18.6
      Never smoked                                                               2392                 56.8                 611                                             56.3                                               314                                                58.8                                        186   51.5                                        74   57.4
  Functional index (Barthel)[^e^](#t002fn005){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                  
      Total or severe dependence                                                 106                  11.1                 14                                              6.4                                                4                                                  4.9                                         10    8.8                                         0    0
      Moderate-mild dependence                                                   294                  30.9                 63                                              28.6                                               29                                                 35.4                                        21    18.4                                        11   64.7[\*](#t002fn006){ref-type="table-fn"}
      No dependence                                                              552                  58.0                 143                                             65.0[\*](#t002fn006){ref-type="table-fn"}          49                                                 59.8                                        83    72.8[\*](#t002fn006){ref-type="table-fn"}   6    35.3
  Days from onset of symptoms to swabbing                                                                                                                                                                                                                                                                                                                                           
      0--2 days                                                                  1569                 37.2                 465                                             42.8                                               261                                                48.9                                        128   35.5                                        47   36.2
      3--4 days                                                                  1595                 37.8                 418                                             38.5                                               199                                                37.3                                        141   39.1                                        58   44.6
      5--7 days                                                                  1053                 25.0                 203                                             18.7[\*](#t002fn006){ref-type="table-fn"}          74                                                 13.9[\*](#t002fn006){ref-type="table-fn"}   92    25.5                                        25   19.2
  Influenza vaccination ≥14 d from ILI onset                                     714                  16.9                 138                                             12.7[\*](#t002fn006){ref-type="table-fn"}          46                                                 8.6[\*](#t002fn006){ref-type="table-fn"}    84    23.3[\*](#t002fn006){ref-type="table-fn"}   5    3.8[\*](#t002fn006){ref-type="table-fn"}

^a^ Comparison group, negative influenza admissions

^b^ Obesity was defined as a body mass index ≥30 for subjects ≥18 years of age and as a z-score of body mass index for age \>2 standard deviations for subjects \<18 years of age. Data were missing for 79 influenza-negative patients and 12 influenza-positive patients.

^c^ Data were missing for 4 influenza-negative patients and 1 influenza-positive patient.

^d^ Data were missing for 3 influenza negative patients and 1 influenza-positive patient.

^e^ Assessed for admissions ≥65 years of age. Data were missing for 21 influenza-negative patients and 12 influenza-positive patients.

\*P\<0.05 vs. influenza negative

In St. Petersburg and Moscow, A(H3N2) was the predominant circulating strain. A first wave due to A(H3N2) (68% of admissions in St. Petersburg and 66% in Moscow) with co-circulating A(H1N1)pdm09 (10% of admissions at both sites) was followed by a late wave of B/Yamagata lineage (7% in St. Petersburg and 19% in Moscow). Circulating strains in Turkey followed a similar pattern, with a first wave in which A(H3N2) predominated (80%) followed by a wave of B/Yamagata lineage (20%) but with no admissions due to A(H1N1)pdm09. In Beijing, influenza A(H3N2) (39%) co-circulated with influenza B/Yamagata lineage (43%) and A(H1N1)pdm09 (15%), and in Valencia, a first wave of A(H1N1)pdm09 (80% of admissions) was followed by a less intense late wave of A(H3N2) (18%) but with no admissions due to influenza B.

Risk factors for admission with laboratory-confirmed influenza {#sec022}
--------------------------------------------------------------

The risk of hospital admission with influenza (vs. influenza-negative admission) was directly related to age, sex, and underlying medical conditions and inversely related to influenza vaccination and time elapsed from onset of symptoms to swabbing ([Table 2](#pone.0154970.t002){ref-type="table"}, [Table 3](#pone.0154970.t003){ref-type="table"} and [S4 Table](#pone.0154970.s006){ref-type="supplementary-material"}).

10.1371/journal.pone.0154970.t003

###### Risk of admission with influenza by site, strain, and patient-related characteristics.

![](pone.0154970.t003){#pone.0154970.t003g}

                                                                                         Influenza positive   Crude OR   Heterogeneity by strain (I^2^)   Adjusted OR                                   
  ------------------------------------------------------------------------------- ------ -------------------- ---------- -------------------------------- ------------- ------- -------- ------- ------ -------
  Days from onset of symptoms to swabbing[^a^](#t003fn002){ref-type="table-fn"}                                                                                                                         
      0--2 days                                                                   2034   465                  22.9       1.00                                                   63.20%   1.00           
      3--4 days                                                                   2013   418                  20.8       0.88                             0.76          1.03    72.10%   0.80    0.69   0.94
      5--7 days                                                                   1256   203                  16.2       0.65                             0.54          0.78    19.40%   0.55    0.45   0.67
  Age[^b^](#t003fn003){ref-type="table-fn"}                                                                                                                                                             
      0--5 months                                                                 557    54                   9.7        1.00                                                   0.0%     1.00           
      6--11 months                                                                315    36                   11.4       1.20                             0.77          1.88    0.0%     1.21    0.77   1.90
      1--4 years                                                                  1086   181                  16.7       1.86                             1.35          2.57    0.0%     1.90    1.36   2.64
      5--17 years                                                                 393    102                  26.0       3.26                             2.28          4.68    0.0%     3.64    2.50   5.30
      18--49 years                                                                1278   349                  27.3       3.50                             2.58          4.75    0.0%     3.95    2.84   5.49
      50--64 years                                                                469    132                  28.1       3.65                             2.58          5.15    68.6%    3.71    2.54   5.44
      65--74 years                                                                398    94                   23.6       2.88                             2.00          4.14    0.0%     3.13    2.07   4.74
      75--84 years                                                                532    106                  19.9       2.32                             1.63          3.30    0.0%     2.51    1.67   3.79
      ≥85 years                                                                   275    32                   11.6       1.23                             0.77          1.95    17.0%    1.39    0.83   2.32
  Sex[^c^](#t003fn004){ref-type="table-fn"}                                                                                                                                                             
      Male                                                                        2927   539                  18.4       1.00                                                   0.0%     1.00           
      Female                                                                      2376   547                  23.0       1.33                             1.16          1.51    0.0%     1.28    1.11   1.49
      Female, non-pregnant                                                        2039   391                  19.1       1.05                             0.91          1.21    0.0%     1.02    0.87   1.19
  Other risk factors[^d^](#t003fn005){ref-type="table-fn"}                                                                                                                                              
      One or more                                                                 1858   430                  23.4       1.28                             1.12          1.47    17.90%   1.29    1.05   1.58
      Cardiovascular disease                                                      874    189                  21.62      1.37                             1.14          1.65    39.6%    1.64    1.33   2.02
      COPD                                                                        746    139                  18.63      1.14                             0.92          1.40    91.4%    1.31    1.03   1.67
      Asthma                                                                      270    76                   28.15      1.94                             1.47          2.58    27.6%    2.25    1.67   3.03
      Immunosuppression                                                           54     16                   29.63      2.09                             1.15          3.77    48.4%    2.25    1.23   4.11
      Diabetes                                                                    495    105                  21.21      1.33                             1.06          1.69    92.3%    1.69    1.29   2.23
      Renal disease                                                               224    57                   25.45      1.69                             1.23          2.32    21.4%    2.11    1.48   3.01
      Rheumatologic disease                                                       23     11                   47.83      4.55                             1.99          10.38   58.5%    5.55    2.34   13.16
      Neuromuscular                                                               113    19                   16.81      1.00                             0.61          1.66    28.5%    1.16    0.69   1.95
      Malignancy (active)                                                         159    29                   18.24      1.11                             0.73          1.67    65.3%    1.18    0.75   1.85
      Liver disease                                                               88     23                   26.1       1.75                             1.08          2.85    0.0%     1.94    1.18   3.19
      Autoimmune disease                                                          48     16                   33.3       2.48                             1.35          4.56    0.0%     2.97    1.58   5.59
      Obese                                                                       496    123                  24.8       1.64                             1.31          2.05    81.8%    1.88    1.46   2.41
  Pregnancy[^e^](#t003fn006){ref-type="table-fn"}                                 337    156                  46.29      2.93                             2.07          4.14    0.0%     3.84    2.48   5.94
      With comorbidity                                                            50     30                   60.0       5.19                             2.25          11.99   0.0%     11.90   2.29   61.70
      No other conditions                                                         287    126                  43.9       2.64                             1.80          3.88    0.0%     3.55    2.21   5.68
  Influenza vaccination[^f^](#t003fn007){ref-type="table-fn"}                     852    138                  16.2       0.71                             0.58          0.86    0.0%     0.61    0.48   0.77

Risk of admission with influenza was determined by comparing influenza-positive and influenza-negative admissions. Strains A(H3N2), A(H1N1)pdm09, and B/Yamagata lineage were considered. Admissions with not-subtyped strains or with B/Victoria lineage were not included because of small sample sizes. I^2^ for the aOR of influenza by site was 0.0%, and the clustering effect by site was P = 1.0^.^.

^a^ Adjusted by sex, age and calendar time splines, comorbidity, hospital admission in previous 12 months, vaccination during the current season, and time to swab.

^b^ Adjusted by health care access, influenza vaccination, underlying conditions, sex, and site as an indicator variable.

^c^ Adjusted by age, comorbidity, smoking habits, socioeconomic status, calendar time, and site as an indicator variable. For heterogeneity estimates, pregnant women were excluded from comparison groups.

^d^ For other risk factors, the first column indicates admissions with the risk factor and influenza positive and the second column indicates the number of subjects with the underlying condition included in the study. The comparison group to estimate the aOR of influenza admission for the risk factor (not shown) is included in admissions without underlying conditions or pregnant, with estimates adjusted for previous vaccination and hospitalizations during the previous 12 months.

^e^ Adjusted by social class, smoking habits, comorbidity, age, and calendar time.

^f^ Adjusted by age, sex, comorbidity, smoking habits, social class, calendar time, time to swab, and site as an indicator variable.

The risk of admission with influenza by site was similar as indicated by low heterogeneity (I^2^ = 0%) and a lack of a clustering effect (data not shown). Frequencies of influenza-positive results were 18.3% (230/1256) for St. Petersburg, 22.3% (281/1260) for Moscow, 23.5% (114/486) for Turkey, 21.4% (90/421) for Beijing, and 19.7% (371/1880) for Valencia.

Age {#sec023}
---

The age distribution of admissions with confirmed influenza varied by site ([S1 Fig](#pone.0154970.s001){ref-type="supplementary-material"}), but overall, all age groups were represented in the pooled dataset ([Table 2](#pone.0154970.t002){ref-type="table"} and [S1 Fig](#pone.0154970.s001){ref-type="supplementary-material"}).

The proportion of admissions with laboratory-confirmed influenza increased from 10% in patients \<12 months of age to 28% in patients 50--64 years of age, whereas in the oldest age groups, influenza positivity decreased with age (24% in the 65--74 year age group to 12% in the \>85 year age group; data not shown). Influenza A(H3N2), A(H1N1)pdm09, and B/Yamagata lineage were identified in patients of all ages ([Fig 2](#pone.0154970.g002){ref-type="fig"}). In St. Petersburg, Moscow, and Turkey, strain A(H3N2) dominated in all age groups except for the 50--64 year age group in Moscow. A(H1N1)pdm09 was predominant in patients \<65 years of age, although in Valencia, it was the dominant strain in all groups. B/Yamagata lineage was largely detected in young patients in Moscow, Turkey, and Beijing. In Beijing, B/Yamagata lineage co-circulated with A(H3N2) and A(H1N1)pdm09 ([Fig 1](#pone.0154970.g001){ref-type="fig"}) but was the dominant strain overall, was observed in all age groups, and was the most common in patients ≥75 years of age ([Fig 2](#pone.0154970.g002){ref-type="fig"}).

![Distribution of positive admissions by site, strain, and age group.](pone.0154970.g002){#pone.0154970.g002}

Age was an independent risk factor for admission with influenza infection ([Table 3](#pone.0154970.t003){ref-type="table"}). Significant heterogeneity by strain (I^2^ = 69%) was observed for the effects of age among the 50--64 year age group ([Table 3](#pone.0154970.t003){ref-type="table"} and [S2 Fig](#pone.0154970.s002){ref-type="supplementary-material"}), in which the probability of A(H1N1)pdm09 infection was higher than A(H3N2) or B/Yamagata lineage.

Sex {#sec024}
---

We did not detect major differences in sex distribution by site ([S4 Table](#pone.0154970.s006){ref-type="supplementary-material"}; p = 0.1970) or by strain ([Table 3](#pone.0154970.t003){ref-type="table"}, I^2^ = 0.0%). Overall, more influenza-positive admissions were female than male (23% vs. 18%; p\<0.0001, [Table 3](#pone.0154970.t003){ref-type="table"}). Excluding pregnant women, 19% of women and 18% of men were influenza positive. After adjustment, the risk of admission with influenza was similar in females and males (aOR = 1.02 \[95% confidence interval (CI), 0.87--1.19\]; I^2^ = 0.0%).

Comorbidities {#sec025}
-------------

Of all admissions with influenza, 60% were in subjects without underlying chronic conditions ([Table 2](#pone.0154970.t002){ref-type="table"}). The proportion of admissions with confirmed influenza without underlying conditions ranged from 96% for patients \<1 year of age to 3% for patients ≥85 years of age ([Fig 3](#pone.0154970.g003){ref-type="fig"}). The remaining 40% of admissions with influenza were in patients with one or more underlying conditions. Patients with comorbidities were 30% more likely to be influenza-positive than patients without comorbidities (aOR = 1.29 \[95% CI, 1.05--1.58\]; [Table 3](#pone.0154970.t003){ref-type="table"}). Overall, influenza was associated with a major risk of severe disease across age groups and underlying conditions ([S2 Fig](#pone.0154970.s002){ref-type="supplementary-material"}).

![Proportion of admissions with underlying conditions by age group.](pone.0154970.g003){#pone.0154970.g003}

Compared with admissions in patients with no comorbidities, the risk (aOR) of severe influenza was increased in patients with cardiovascular disease (1.64 \[95% CI, 1.33--2.02\]), asthma (2.25 \[95% CI, 1.67--3.03\]), immunosuppression (2.25 \[95% CI, 1.23--4.11\]), renal disease (2.11 \[95% CI, 1.48--3.01\]), liver disease (1.94 \[95% CI, 1.18--3.19\]), autoimmune disease (2.97 \[95% CI, 1.58--5.59\]), or pregnancy (3.84 \[95% CI, 2.48--5.94\]). For most of comorbidities, the risk was similar for strains A(H3N2), A(H1N1), and B/Yamagata lineage (I^2^\<50%; [Table 3](#pone.0154970.t003){ref-type="table"} and [Fig 4](#pone.0154970.g004){ref-type="fig"}), although the risk varied by strain (I^2^ \>50%) and was mostly associated with A(H1N1)pdm09 for chronic obstructive pulmonary disease (COPD) (aOR = 2.59 \[95% CI, 1.85--3.62\]) and diabetes (aOR = 3.72 \[95% CI, 2.58--5.34). In the case of obesity, the adjusted risk by strain was not homogenous (I^2^ = 82%) but was significant for A(H1N1)pdm09 (aOR = 3.11 \[95% CI, 2.18--4.43\]) and A(H3N2) (aOR = 1.47 \[95% CI, 1.02--2.11). The number of B/Yamagata lineage admissions was similar for COPD, diabetes, and obesity, although few patients had these comorbidities ([Fig 4](#pone.0154970.g004){ref-type="fig"}).

![Risk of admission with influenza related to underlying conditions.](pone.0154970.g004){#pone.0154970.g004}

Pregnancy {#sec026}
---------

A total of 627 admissions were women 15--45 years of age (393 in Moscow, 127 in St. Petersburg, and 82 in Valencia, 14 in Turkey, and 11 in Beijing). Of these, 327 in Moscow (83%), 1 in St. Petersburg (1%), and 8 in Valencia (11%) were pregnant. No pregnant women 15--45 years of age were recruited in Turkey or Beijing.

Pregnancy was a significant and independent risk factor for severe influenza disease. Amongst women 15--45 years of age, 46% of pregnant women vs. 23% of non-pregnant women were positive for influenza. In the subset of pregnant women with comorbidities, 60% of pregnant women vs. 22% of non-pregnant women were positive for influenza. The combination of pregnancy and comorbidity appeared to contribute to the development of severe influenza disease, although the interaction test was not significant (p = 0.0650). The aOR for admission with influenza in pregnant women vs. non-pregnant women was 11.90 (95% CI, 2.29--61.70) when comorbidities were present and 3.55 (95% CI, 2.21--5.68) in the absence of comorbidities ([Table 3](#pone.0154970.t003){ref-type="table"}). This increased risk, independent of additional comorbidity, was observed for all three influenza viruses (I^2^ = 0.0%; [Table 3](#pone.0154970.t003){ref-type="table"} and [Fig 4](#pone.0154970.g004){ref-type="fig"}).

The rate of laboratory-confirmed influenza was 43% for pregnant women in the first trimester, 47% in the second trimester, and 47% in the third trimester. This pattern was similar across strains (p = 0.311) and for pregnancies with and without confirmed influenza (p = 0.859) (data not shown). Compared to non-pregnant women, the risk for hospitalization due to influenza (vs. influenza-negative hospitalization) was significantly higher during all trimesters of pregnancy. The aOR for influenza positivity was higher in the second (4.77 \[95% CI, 2.40--9.53\]) and third trimester (aOR = 4.72 \[95% CI, 2.33--9.55\]) than in the first trimester (4.18 \[95% CI, 1.92--9.10\]), although CIs were overlapping.

Other risk factors, vaccination status {#sec027}
--------------------------------------

Of the 5303 patients included, 852 (16%) were vaccinated at least 14 days before symptoms onset. By site, the rates were 1% in St. Petersburg, 4% in Moscow, 11% in Turkey, 12% in Beijing, and 37% in Valencia ([S4 Table](#pone.0154970.s006){ref-type="supplementary-material"}). Overall, 138 (16.2%) admissions with influenza were in vaccinated subjects and 942 (21.4%) were in non-vaccinated subjects. The aOR of admission with influenza in vaccinated compared to unvaccinated subjects was 0.61 (95% CI \[0.48--0.77\]), with no heterogeneity by strain (I^2^ = 0.0%)

Complications and outcomes in admissions with influenza {#sec028}
-------------------------------------------------------

During the study period, 143 ICU admissions and 71 in-hospital deaths were recorded. Of the 143 ICU admissions, 31 (2.9%) were influenza-positive and 112 (2.7%) were influenza-negative (p = 0.8910). Of the 71 in-hospital deaths, 15 (1.4%) were influenza-positive and 56 (1.3%) were influenza-negative (p = 0.7220) ([Table 4](#pone.0154970.t004){ref-type="table"}). Influenza infection was not a significant risk factor for ICU admission (aOR = 0.95 \[95% CI, 0.60--1.52\]) or death (aOR = 1.22 \[0.60--2.44\]) ([Fig 5](#pone.0154970.g005){ref-type="fig"}).

![Outcomes and complications among admissions with influenza.](pone.0154970.g005){#pone.0154970.g005}
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###### Indicators of severity, complications, and major diagnoses at discharge.

![](pone.0154970.t004){#pone.0154970.t004g}

                                                                                              Negative   Influenza (all)   A(H1N1)pdm09   A(H3N2)[^a^](#t004fn001){ref-type="table-fn"}   B (all)[^b^](#t004fn002){ref-type="table-fn"}                                     
  ------------------------------------------------------------------------------------------- ---------- ----------------- -------------- ----------------------------------------------- ----------------------------------------------- -------- ----- ------ ---- ------ --------
  Indicator of severity                                                                                                                                                                                                                                                     
      ICU admission                                                                           112        2.7               31             2.9                                             14                                              3.9      17    3.0    0    0.0    0.7220
      In-hospital death                                                                       56         1.3               15             1.4                                             7                                               1.9      8     1.4    0    0.0    0.8910
      Length of stay, median (interquartile range)                                            6 (4--8)   6 (4--8)          5 (3--8)       6 (4--8)                                        6 (4--8)                                        0.2593                            
  Pulmonary complications                                                                                                                                                                                                                                                   0.0000
      Pneumonia                                                                               744        17.6              194            17.9                                            95                                              26.3     79    13.8   20   13.2   
      Exacerbation of COPD                                                                    183        4.3               42             3.9                                             31                                              8.6      6     1.0    5    3.3    
      Respiratory failure                                                                     67         1.6               25             2.3                                             15                                              4.2      10    1.7    0    0.0    
      Asthma exacerbation                                                                     32         0.8               16             1.5                                             12                                              3.3      4     0.7    0    0.0    
      Pulmonary collapse                                                                      9          0.2               1              0.1                                             1                                               0.3      0     0.0    0    0.0    
      Hemoptysis                                                                              1          0.0               0              0.0                                             0                                               0.0      0     0.0    0    0.0    
      Acute respiratory distress syndrome                                                     34         0.8               10             0.9                                             8                                               2.2      2     0.3    0    0.0    
      Bronchiolitis                                                                           210        5.0               41             3.8                                             5                                               1.4      24    4.2    12   7.9    
      Upper respiratory infection                                                             1947       46.2              261            24.0                                            42                                              11.6     176   30.7   43   28.5   
  Metabolic failure                                                                                                                                                                                                                                                         0.1410
      Acute renal failure                                                                     60         1.4               10             0.9                                             6                                               1.7      4     0.7    0    0.0    
      Diabetic coma                                                                           5          0.1               0              0.0                                             0                                               0.0      0     0.0    0    0.0    
      Fluid/electrolyte/acid-base/balance disorder                                            47         1.1               8              0.7                                             5                                               1.4      3     0.5    0    0.0    
  Cardiovascular processes                                                                                                                                                                                                                                                  0.0828
      Acute myocardial infraction                                                             4          0.1               0              0.0                                             0                                               0.0      0     0.0    0    0.0    
      Acute heart failure                                                                     1          0.0               1              0.1                                             1                                               0.3      0     0.0    0    0.0    
      Arterial or venous embolism                                                             0          0.0               1              0.1                                             0                                               0.0      1     0.2    0    0.0    
      Pulmonary embolism                                                                      1          0.0               0              0.0                                             0                                               0.0      0     0.0    0    0.0    
      Cardiac arrest                                                                          0          0.0               1              0.1                                             0                                               0.0      1     0.2    0    0.0    
      Malignant hypertension                                                                  16         0.4               5              0.5                                             3                                               0.8      2     0.3    0    0.0    
  Systemic inflammatory response syndrome, shock, or disseminated intravascular coagulation   19         0.5               4              0.4                                             1                                               0.3      3     0.5    0    0.0    0.7080
  Neurologic diagnoses                                                                                                                                                                                                                                                      0.2430
      Altered mental status                                                                   4          0.1               1              0.1                                             1                                               0.3      0     0.0    0    0.0    
      Convulsions                                                                             1          0.0               0              0.0                                             0                                               0.0      0     0.0    0    0.0    
      Meningitis                                                                              4          0.1               0              0.0                                             0                                               0.0      0     0.0    0    0.0    
      Anoxic brain damage                                                                     0          0.0               1              0.1                                             0                                               0.0      1     0.2    0    0.0    
  Major discharge diagnoses                                                                                                                                                                                                                                                 
      Influenza                                                                               114        2.7               487            44.8                                            161                                             44.6     269   46.9   57   37.7   0.0000
      Pneumonia                                                                               801        19.0              99             9.1                                             34                                              9.4      52    9.1    13   8.6    
      Other respiratory disease                                                               2369       56.2              318            29.3                                            87                                              24.1     179   31.2   52   34.4   
      Cardiovascular                                                                          231        5.5               48             4.4                                             27                                              7.5      20    3.5    1    0.7    
      Other                                                                                   702        16.6              134            12.3                                            52                                              14.4     54    9.4    28   18.5   

^a^ 40 non-subtyped A influenza were considered as A(H3N2)

^b^ 3 B/Victoria lineage and 18 non-subtyped B influenza viruses are grouped under B (all)

ICU admission occurred in 14 (4%) patients infected with A(H1N1) and 17 (3%) patients infected with A(H3N2) compared to 112 (3%) influenza-negative patients. In-hospital deaths occurred in 7 (1.9%) patients infected with A(H1N1) and 8 (1.4%) patients infected with A(H3N2) compared to 56 (1.3%) influenza-negative patients ([Table 4](#pone.0154970.t004){ref-type="table"}). Overall and by strain, there was a trend for influenza as a risk factor for ICU admission, mostly in patients infected with A(H1N1)pdm09, although 95% CIs were overlapping ([Fig 6](#pone.0154970.g006){ref-type="fig"}). We also observed a trend for death in patients infected with A(H3N2), although, again, 95% CIs were overlapping.

![ICU admission and in hospital death by age group and RT-PCR result.\
Capped spikes show 95% confidence intervals.](pone.0154970.g006){#pone.0154970.g006}

The mean length of hospital stay was similar between patients with and without confirmed influenza ([Table 4](#pone.0154970.t004){ref-type="table"}) and between patients with A(H3N2), A(H1N1), or B/Yamagata lineage influenza infection (data not shown; p = 0.752).

At hospital discharge, 586 (54%) admissions with confirmed influenza were allocated discharge codes for influenza or pneumonia compared to 915 (22%) admissions without confirmed influenza (p\<0.001) ([Table 4](#pone.0154970.t004){ref-type="table"}). Another 182 (17%) admissions with confirmed influenza were allocated discharge codes unrelated to influenza or other respiratory conditions.

Discussion {#sec029}
==========

This study showed a prolonged and variable pattern of influenza circulation and severe disease during the 2013/2014 Northern hemisphere influenza season. The influenza strains varied between sites and, during the course of a full season, within each site. Over a 20-week span, influenza A was the predominant subtype, with more A(H3N2) than A(H1N1). Fewer hospitalizations were caused by B/Yamagata lineage, and the fewest were due to B/Victoria lineage. Three patterns of circulation were observed: A(H3N2)-dominant, A(H1N1)-dominant, and mixed. Most sites experienced more than one wave of influenza, with each wave due to different strains. Overall, these findings agree with the patterns of circulation reported by the World Health Organization for the 2013/2014 Northern hemisphere influenza season \[[@pone.0154970.ref028]\].

Hospital admissions with laboratory-confirmed influenza occurred in all age groups, although the probability of an influenza-positive result amongst admitted patients was lowest in the oldest and youngest age groups. We also observed a larger burden of non-influenza related hospitalizations in the youngest (\< 1 year) and oldest (≥85 years) patients, which could explain the lower relative burden of influenza infection amongst all acute respiratory disease admissions in these age groups. This would also explain the age-dependent pattern of the odds ratio for influenza infection, which agrees with our results from 2012--2013 \[[@pone.0154970.ref006]\] and has also been reported in other studies \[[@pone.0154970.ref029],[@pone.0154970.ref030]\] and in a recent extensive review \[[@pone.0154970.ref010]\]. In this study, we do not report age-specific influenza incidence rates, where a J- or U- shape curve would be expected \[[@pone.0154970.ref031],[@pone.0154970.ref032]\] because data were not available on the catchment populations of study hospitals. Nevertheless, our results demonstrate that severe influenza is a significant threat for all age groups.

In this study, patients without underlying conditions accounted for 60% of admissions with influenza. These numbers are based on active surveillance using a common protocol, in contrast to surveillance based on the judgment of a clinician, where the percent of admissions without comorbidities can be much lower \[[@pone.0154970.ref033]\]. The fraction of influenza-positive patients without underlying conditions depended on age, with the highest rate (96%) in patients \<1 year of age and the lowest rate (3%) in patients ≥85 years of age. A high rate of young children hospitalized with laboratory-confirmed influenza without comorbidities has been noted elsewhere \[[@pone.0154970.ref034],[@pone.0154970.ref035]\]. Young adults without comorbidities were hospitalized with influenza at a high rate during the 2009 A(H1N1)pdm09 pandemic \[[@pone.0154970.ref036]\]. Thus, influenza is of broad public health relevance across all age groups and risk profiles.

Amongst the patients included in this study, having a comorbidity, especially asthma, increased the risk of being influenza positive by 30%, irrespective of influenza strain \[[@pone.0154970.ref037]\]. In some instances, such as in patients with COPD, diabetes, and obesity, this risk was specific for strain A(H1N1)pdm09. Our findings are consistent with the hypothesis that influenza causes severe disease by over-stimulating the immune response and exacerbating underlying conditions \[[@pone.0154970.ref038]\].

Pregnancy was a major and outstanding risk factor for influenza-positive admission, regardless of strain. Notably, the risk was elevated throughout all trimesters. Comorbidity increased the risk of influenza-positive admission in pregnant women several fold. These findings, based on a significant number of included admissions in pregnant women, strongly support the current recommendation that pregnant women be prioritized for influenza vaccination \[[@pone.0154970.ref039]\]. Our observations were the most recent of several demonstrating that pregnant women are at increased risk for severe seasonal influenza due to A(H1N1)pdm09 \[[@pone.0154970.ref040]--[@pone.0154970.ref044]\], and they provide information on the risk posed during pregnancy by A(H3N2) and B/Yamagata lineage infection not previously described elsewhere.

Our observations should help address some of the concerns about the quality of the evidence supporting the definition of groups at risk for severe influenza \[[@pone.0154970.ref010]\]. In addition, our observations showed that, after adjustment and regardless of strain, influenza vaccination was associated with a consistent reduction in the risk of hospitalization with influenza.

Finally, we did not find an association between confirmed influenza and ICU admission or in-hospital death. However, this was based on relatively few deaths and ICU admissions so that the analysis was underpowered.

Considerations and limitations {#sec030}
------------------------------

Interpretation of these findings should be made in light of the fact that the number of patients was insufficient to perform calculations for certain risk factors or comorbidities or to analyze by certain subgroups, such as by age group. To perform these analyses with sufficient power and therefore draw meaningful conclusions, data will have to be pooled over several seasons. Such data pooling is only possible if a common core protocol is consistently applied over several seasons and across sites, as in the GIHSN. A pooled analysis awaits completion of data accrual and careful decisions about the best way to perform and present the results.

In this study, we did not perform follow-up after discharge as others have done \[[@pone.0154970.ref009]\]. We also did not have population denominators, so probabilities or risks were calculated in reference to included admissions and should not be interpreted as being necessarily representative of the full population for each country. Nonetheless, as with all analysis based on surveillance data, it is reasonable to make certain overall conclusions that apply to the population in general \[[@pone.0154970.ref045]\].

To limit false negatives, we excluded patients swabbed more than 7 days after symptom onset because we and others \[[@pone.0154970.ref046]\] have found an association between time after symptom onset and influenza positivity. This probably does not explain the proportion of influenza-negative patients and its variability with age. Furthermore, the adjusted probability of a positive result for influenza was homogeneous across sites. Although using a test-negative study to examine other risk factors for influenza might be problematic when the factors are also associated with the chance of inclusion in the control group, we used only admissions without co-morbidity as a comparison group, and our approach minimized selection bias and ensured comparability and exchangeability of comparison groups. Our approach should also have reduced information bias on outcome ascertainment and should substantially add to the precision of our estimates of odds ratios for hospitalization with influenza.

The protocol and study management used by GIHSN \[[@pone.0154970.ref014]\] is designed to address the majority of limitations identified for studies monitoring severe influenza \[[@pone.0154970.ref008]--[@pone.0154970.ref010]\]. In particular, we used an active and prospective ascertainment of eligible admissions, we followed a common core protocol, and we used the same inclusion criteria and case definition across sites. We also performed systematic sampling according to protocol instead of using clinician judgment, and we used RT-PCR to detect influenza viruses in combined nasopharyngeal swabs, two steps that have been described as adequate for surveillance schemes \[[@pone.0154970.ref047],[@pone.0154970.ref048]\]. Accrual of information during consecutive seasons and growth of the GIHSN, coupled with application of this common core protocol, should allow us to pool data on strain effects across seasons and sites with minor site strain-subject effects and should allow for a more robust analysis of the severe consequences of influenza.

Hospital admission with influenza was used as a correlate of severe influenza to allow for non-selective objective and traceable enumeration. This also allowed for useful and relevant comparison groups for influenza (overall and by strain) for the existing risk group and for severe outcomes. Due to similarities in risk profiles between admissions with and without influenza \[[@pone.0154970.ref049]\], examining the distribution of risk factors among hospitalized subjects may not be ideal. However, admissions are considered a relevant outcome for public health policy purposes \[[@pone.0154970.ref011],[@pone.0154970.ref012]\], and in the majority of cases, severe outcomes (ICU, prolonged stay, and death during hospitalization) are already included in the definition of severe influenza \[[@pone.0154970.ref009]\].

Conclusions {#sec031}
===========

The current analysis demonstrated that influenza causes severe outcomes during an extended period of the year in the Northern hemisphere, although the strains vary between sites and within sites over time. Our results confirmed the impact of previously identified risk groups for hospital admission with influenza. In particular, we provided needed data to better define the risk associated with pregnancy \[[@pone.0154970.ref010],[@pone.0154970.ref041]\]. Our results also demonstrate that influenza infection substantially increases the risk of hospital admission throughout pregnancy, a risk that is further increased by underlying conditions.

The approach used by the GIHSN provides clear and relevant information on severe influenza epidemiology, by strain and different population groups. Progressive accrual of information by the GIHSN during ensuing seasons will provide a more precise and relevant definition of the burden of severe disease caused by influenza and will provide for a better understanding of influenza as an individual, local, and global health problem.
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